PETACH TIKVA, Israel, September 28, 2016 /PRNewswire/ --
Emerald Medical Applications Corp. (OTCQB: MRLA) ("Emerald" or the "Company"), the Israeli-based company engaged in the development and sale of DermaCompare™, its proprietary artificial intelligence technology for the early diagnosis of melanoma and other skin cancers, today announced that it has signed a term sheet with the Hispanic Professionals Association Inc. New York ("AHPSI") to sponsor the marketing of the Dermacompare technology to its physician and nurse members.
AHPSI is a society dedicated to the education of Hispanic doctors, nurses and other allied medical professionals, which it does through 12 annual Community Health Fairs and over 30 mini-conferences throughout the Mid Atlantic region.
Emerald's patent-pending Dermacompare platform integrates artificial intelligence and state-of-the-art image comparison technology with a free mobile App to enable users with a smart phone to photo their skin, and have those pictures automatically compared to a database of millions of known moles in the cloud, as well as their own previously taken images. The underlying technology then identifies suspicious moles for Melanoma and sends a detailed analysis to the patient's doctor to schedule an appointment. The App based technology is FDA registered and HIPAA compliant.
Adi Zamir, Emerald's CEO, commented on the announcement, "We are very excited to sponsor AHPSI in its effort to educate its members about our technology. AHPSI is one of the most recognized voices within the Hispanic medical professional community in the US, representing thousands of physicians, nurses and other healthcare professionals in New York and the surrounding areas."
Ms. Zamir went on to say, "We anticipate this partnership will result in thousands of patients downloading our App to avail themselves of the Dermacompare platform, and look forward to working with the AHPSI community on our collective mission to increase awareness about the importance of early detection in the diagnosis and treatment of Melanoma and other skin cancers."
Dr. Aritmedes Restituyo, President of AHPSI said: "Total Body Photography has been shown to lower the number of Melanoma deaths nearly 50% over five years. DermaCompare's free App puts that capability right in the hands of patients, and this partnership will help us educate our members on the detection and monitoring of skin cancer through our annual health fairs and conferences, and ultimately help save lives."
Notice Regarding Forward-Looking Statements
This Presentation does not constitute an offer to purchase securities of the Company or an invitation to accept such offers, and is solely intended to furnish general information, incomplete by its nature, in the course of providing institutional investors and analysts with explanations regarding the Company. This Presentation was prepared as an abstract and for convenience only, and cannot substitute for examination of such reports made available to the public by the Company, which include the entire information regarding the Company, prior to any decision regarding investment in securities of the Company. This Presentation includes forward looking information, as defined in the Israeli Securities Law, 5728-1968. Such information includes, inter alia, forecasts, objectives, evaluations and assessments, including such information presented by way of illustrations and/or graphs and/or tables, and referring to future events and/or issues the realization of which is uncertain and out of the Company's control. Forward looking information does not constitute verified fact and is by its nature subject to substantial non‐realization risks. Such information is uncertain, may not be accurately assessed in advance, and its realization or non-realization is effected, inter alia, by risk factors characterizing the Company's activity as well as developments in the general surroundings and external factors influencing the Company's activity, which cannot be assessed in advance and are out of the Company's control. In view of the above, viewers of this Presentation are hereby warned that the Company's actual future achievements and results may differ substantially from those exhibited in the forward looking information presented herein. Moreover, forecasts and forward looking assessments are based on such data and information available to the Company when preparing the Presentation, and the Company does not undertake to update and/or change any such forecast and/or assessment so as to reflect events and/or circumstances occurring after the preparation of this Presentation.
About Emerald Medical Applications Corp
Emerald Medical Applications is an Israeli-based medical technology company that utilizes proprietary military image processing technology and state of the art data analytics to improve the analysis of medical images. Emerald's flagship solution, DermaCompare™, is an FDA Class #1 approved, HIPAA-compliant, skin cancer (melanoma) screening platform that enables physicians to identify and monitor changes in their patients' skin health, specifically the early detection of cancerous moles and skin anomalies.
The DermaCompare™ patient application is available in iOS or Android based platforms and works using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography ("TBP") images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patient's previous Total Body Photography images, which will dramatically enhance a physician's ability to detect Melanoma earlier, more accurately and more efficient than other means of diagnosis
For more information, visit :http://www.dermacompare.com/
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements, about Emerald's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Emerald or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Emerald with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Emerald's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Emerald's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Emerald's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Emerald's filings with the SEC. In addition, Emerald operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Emerald does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Reference is made to the disclosure under "risk factors" included in our Registration Statement on Form S-1 which was declared effective by the U.S. Securities and Exchange Commission on January 20, 2016.
Adi Zamir, CEO
SOURCE Emerald Medical Applications Corp.